| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 26 |
| 1 | CYCLOPHOSPHAMIDE | 22 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 22 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 22 |
| 4 | DOXORUBICIN | 16 |
| 5 | ETOPOSIDE | 15 |
| 6 | CARBOPLATIN | 13 |
| 7 | PREDNISONE | 11 |
| 8 | DEXAMETHASONE | 9 |
| 9 | DEXAMETHASONE 1.5 MG | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FILGRASTIM-AAFI | 1 | 0.0015 |
| 1 | ETOPOSIDE PHOSPHATE | 2 | 0.0012 |
| 2 | EPCORITAMAB-BYSP | 1 | 0.0007 |
| 3 | CIDOFOVIR ANHYDROUS | 1 | 0.0007 |
| 4 | INOTUZUMAB OZOGAMICIN | 1 | 0.0003 |
| 5 | ZANUBRUTINIB | 1 | 0.0002 |
| 6 | ETOPOSIDE | 15 | 0.0002 |
| 7 | VINCRISTINE SULFATE | 6 | 0.0002 |
| 8 | IFOSFAMIDE FOR INJECTION | 4 | 0.0002 |
| 9 | DOXORUBICIN HYDROCHLORIDE | 6 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 26 |
| 1 | Alkylating Drug [EPC] | 23 |
| 2 | Corticosteroid [EPC] | 23 |
| 3 | Topoisomerase Inhibitor [EPC] | 15 |
| 4 | Platinum-based Drug [EPC] | 14 |
| 5 | Microtubule Inhibitor [EPC] | 6 |
| 6 | Aldosterone Antagonist [EPC] | 5 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 4 |
| 8 | BCL-2 Inhibitor [EPC] | 3 |
| 9 | Nucleoside Metabolic Inhibitor [EPC] | 3 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD22-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 1 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 2 | Topoisomerase Inhibitor [EPC] | 15 | 0.0002 |
| 3 | CD19-directed Chimeric Antigen Receptor [EPC] | 1 | 0.0001 |
| 4 | Alkylating Drug [EPC] | 23 | 0.0001 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 26 | 0.0001 |
| 6 | Platinum-based Drug [EPC] | 14 | 0.0001 |
| 7 | BCL-2 Inhibitor [EPC] | 3 | 0.0000 |
| 8 | Microtubule Inhibitor [EPC] | 6 | 0.0000 |
| 9 | Aldosterone Antagonist [EPC] | 5 | 0.0000 |